The webinar will feature a presentation by Key Opinion Leaders (KOLs), Puja Khanna, M.D., M.P.H. (University of Michigan – Michigan Medicine) and Robert Terkeltaub, M.D., (University of California San Diego).  Both experts will discuss the current treatment landscape for gout and unmet medical need in treating the pain, swelling, and discomfort associated with gout flares. Both experts, along with management, will also provide perspectives on the recent results from the first Phase 2 study from the TARGETS trial of Dyve’s lead clinical candidate, DYV702, for the treatment of pain associated with acute gout flares.

Despite approximately 10 million patients in the U.S. and over 1 million attacks each year, gout is a condition that has had very little innovation beyond the current standard of care (recommendations from the American College of Rheumatology in 2020 involving urate-lowering therapy (ULT) as prophylaxis, and colchicine, NSAIDs, or glucocorticoids to treat acute flares). DYV702 demonstrated a statistically significant improvement in overall response rate, near-elimination of rescue medication usage, and improvement in physical function.  In addition, per protocol analyses demonstrated significance across 24-hour endpoints.  The improvements in gout flare pain relative to existing treatment options, and previous trials of other agents, highlight the potential for this simple, well-tolerated and on-demand treatment.  Further details regarding all primary and secondary endpoints, as well as safety and tolerability will be provided during the event.

A live Q&A session will follow the formal presentations.